文献速递核素与放射性配体治疗骨显像与常规 SPECT放射性药物与辐射防护

α粒子发射体标记抗GD2人源化抗体治疗骨肉瘤的疗效:一项概念验证研究

Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-18

研究将抗GD2人源化抗体hu3F8用锕-225标记,在骨肉瘤原位小鼠异种移植模型和自发骨肉瘤犬中评估[225Ac]Ac-DOTA-hu3F8的安全性与疗效。两种模型中均证实显著抗肿瘤活性并改善总生存,小鼠肿瘤生长较未治疗队列延迟16-18天,组织学显示放射性肾毒性表现但提示肾功能快速恢复。作者认为基于hu3F8的α粒子治疗是骨肉瘤有前景的治疗策略。

要点

  • 小鼠骨肉瘤原位异种移植中,[225Ac]Ac-DOTA-hu3F8使肿瘤生长较未治疗队列延迟16-18天。
  • 两例犬自发骨肉瘤患者总生存时间分别为211天和437天,转移后生存分别为111天和84天。
  • 组织学可见放射性肾毒性,表现为肾上皮细胞核增大及提示多倍体,提示放疗损伤后肾功能快速恢复。

核心结论

  • 本研究凸显基于hu3F8的α粒子治疗作为骨肉瘤有前景治疗策略的潜力。

研究设计与样本

  • 将hu3F8抗体用锕-225标记,在骨肉瘤原位小鼠异种移植模型和犬自发骨肉瘤中评估[225Ac]Ac-DOTA-hu3F8的安全性与治疗疗效。

主要发现

  • 小鼠异种移植中,生物发光成像显示肿瘤生长较未治疗队列延迟16-18天,治疗后33天磁共振成像及死后微计算机断层扫描和平面显微放射摄影进一步验证。
  • 组织学评估显示放射性肾毒性,表现为肾上皮细胞核增大及提示多倍体,提示放疗损伤后肾功能快速恢复。
  • 两例犬患者治疗延迟了转移扩散,总生存时间分别为211天和437天,有记录转移后生存分别为111天和84天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current treatments for osteosarcoma (OS) have a poor prognosis, particularly for patients with metastasis and recurrence, underscoring an urgent need for new targeted therapies to improve survival. Targeted alpha-particle therapy selectively delivers cytotoxic payloads to tumors with radiolabeled molecules that recognize tumor-associated antigens. We have recently demonstrated the potential of an FDA approved, humanized anti-GD2 antibody, hu3F8, as a targeted delivery vector for radiopharmaceutical imaging of OS. The current study aims to advance this system for alpha-particle therapy of OS. METHODS: The hu3F8 antibody was radiolabeled with actinium-225, and the safety and therapeutic efficacy of the [225Ac]Ac-DOTA-hu3F8 were evaluated in both orthotopic murine xenografts of OS and spontaneously occurring OS in canines. RESULTS: Significant antitumor activity was proven in both cases, leading to improved overall survival. In the murine xenograft's case, tumor growth was delayed by 16-18 days compared to the untreated cohort as demonstrated by bioluminescence imaging. The results were further validated with magnetic resonance imaging at 33 days after treatment, and microcomputed tomography and planar microradiography post-mortem. Histological evaluations revealed radiation-induced renal toxicity, manifested as epithelial cell karyomegaly and suggestive polyploidy in the kidneys, suggesting rapid recovery of renal function after radiation damage. Treatment of the two canine patients delayed the progression of metastatic spread, with an overall survival time of 211 and 437 days and survival beyond documented metastasis of 111 and 84 days, respectively. CONCLUSION: This study highlights the potential of hu3F8-based alpha-particle therapy as a promising treatment strategy for OS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liatsou I, Fu Y, Li Z, et al. Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study. Eur J Nucl Med Mol Imaging. 2023. PMID: 38108831. doi:10.1007/s00259-023-06528-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。